Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab

BACKGROUND: Targeting drugs to their sites of action to overcome the systemic side effects associated with most antineoplastic agents is still a major challenge in pharmaceutical research. In this study, the monoclonal antibody, trastuzumab, was used as a targeting agent in nanoparticles carrying th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yousefpour, Parisa, Atyabi, Fatemeh, Vasheghani-Farahani, Ebrahim, Movahedi, Ali-Akbar Mousavi, Dinarvand, Rassoul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181058/
https://www.ncbi.nlm.nih.gov/pubmed/21976974
http://dx.doi.org/10.2147/IJN.S21523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181058/
https://www.ncbi.nlm.nih.gov/pubmed/21976974
http://dx.doi.org/10.2147/IJN.S21523

Ejemplares similares